市場調査レポート

商品コード

1801145

ヒト成長ホルモンの市場規模、シェア、動向、予測：用途、流通チャネル、投与経路、地域別、2025年～2033年

Human Growth Hormone Market Size, Share, Trends and Forecast by Application, Distribution Channel, Route of Administration, and Region, 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 119 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 449,220円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 599,010円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 748,800円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.79円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ヒト成長ホルモンの世界市場規模は、2024年に61億1,000万米ドルとなりました。今後、IMARC Groupは、2033年までに同市場が114億7,000万米ドルに達し、2025～2033年のCAGRは6.88%になると予測しています。現在、北米が市場を独占しており、2024年には42.8%という大きな市場シェアを占めています。医療インフラが発達していること、成長ホルモン欠乏症、ターナー症候群、プラダー・ウィリー症候群などのHGH関連疾患の発生率が高いことから、市場は力強く成長しています。有利な償還政策、ファイザーやイーライリリーなどの大手製薬会社の利用可能性、組換えDNA法の進歩という形での政府の支援も、ヒト成長ホルモン市場シェアに拍車をかけています。

ヒト成長ホルモン（HGH）市場は、低身長症を含む成長ホルモンの欠乏症の増加により急成長を遂げています。バイオテクノロジーと組換えDNA技術の向上により、合成HGHの生産が可能になったため、入手しやすさと価格が向上しています。人口の高齢化とそれに伴う老齢によるホルモン不足も、HGH療法に対する強い需要を生み出しています。長時間作用型製品や使いやすいデバイスなど、ドラッグデリバリーシステムの技術的進歩は、患者のコンプライアンスと使いやすさを向上させています。さらに、HGH療法の利点に関する患者や医療従事者の意識の高まりも、市場の成長を後押ししています。新興経済諸国におけるヘルスケア・インフラの開拓は、市場浸透のための未開拓の可能性を提供します。さらに、個別化医療や精密治療の動向の高まりは、専門的なHGH療法を可能にし、収量の最大化と副作用の軽減を実現します。

米国は、その先進的な医療制度、強固な規制状況、最先端の製薬状況により、主要な市場破壊者として際立っています。米国企業は、長時間作用型製剤や患者に優しい製剤など、世界中の治療パターンに革命をもたらす新しいHGH製品を生み出す最前線にいます。アメリカの積極的な規制システムは、革新的な治療法の迅速な承認と商業化をサポートし、他の世界市場をリードしています。さらに、患者や医療従事者の意識が高いことも、新しい治療法の早期導入に拍車をかけています。研究とバイオテクノロジーへの多額の投資は、製品の革新と競争をさらに加速させ、世界のプレーヤーは米国の基準に追いつくことを余儀なくされています。個別化医療とデジタルヘルス・ソリューションの導入も、治療の精度と患者のコンプライアンスを向上させる。その結果、米国は製品開発を形成すると同時に市場の期待も変化させ、世界のHGH市場空間におけるトレンドセッターでありディスラプターであると位置づけています。

ヒト成長ホルモン市場動向：

個別化治療や予防治療、その他の疾患への注目の高まり

ヒト成長ホルモン（HGH）業界を変革する最も顕著な動向の一つは、個別化・予防ヘルスケア手法の重視の高まりです。医学が進化し続けるにつれ、治療は一般的なプロトコルから、患者の遺伝、習慣、個々のホルモン欠乏に特化したカスタマイズされたレジメンへと移行しつつあります。この動向はHGH市場において特に重要であり、治療期間や投与量は患者の年齢、状態、代謝反応によって劇的に異なる可能性があります。医師は、診断ツールやデジタル・モニター技術を利用してホルモン療法を改良し、より少ない副作用でより良い結果を出すようになってきています。HGHは、欠乏症のほか、加齢性変性、外傷の回復、慢性疲労などについても研究されています。さらに、ターナー症候群やその他の成長関連疾患の有病率の増加は、市場の成長を促進する重要な要因のひとつです。ターナー症候群は、主に女性が罹患する染色体異常で、X染色体の完全または部分的な喪失を特徴とし、女性の赤ちゃんの約2,500人に1人の割合で発生します。成長ホルモンは、この病気の症状の一部を回復させるために投与されることが多く、それによって世界中でHGH医薬品の需要が増加しています。こうした用途の拡大は、ウェルネスと長寿ソリューションに対する消費者の関心の高まりに応えつつ、市場範囲を拡大し、ヒト成長ホルモン市場の成長をさらに後押ししています。

ドラッグデリバリーシステムの技術的進歩

ドラッグデリバリーシステムにおけるいくつかの進歩も、ヒト成長ホルモン市場の成長と革新を推進する主要動向です。従来のHGH療法は、小児や高齢の患者のコンプライアンスに課題を課していたため、頻繁に、さらには毎日注射をするという形で行われてきました。これを解決するために、製薬業界は長期持続型製剤、ペン型デバイス、さらには経皮パッチや自動注射器の開発に継続的に投資しています。これらの技術は、患者の利便性と治療負担の軽減を大幅に改善し、HGH療法をより利用しやすく、負担の少ないものにしています。ドラッグデリバリー技術が向上すれば、血中ホルモン濃度の安定性も改善され、副作用が減少し、治療効果が向上します。したがって、この動向は、バイオ医薬品市場における患者中心の製品設計への一般的なシフトの延長線上にあります。さらに、競争の激化に伴い、製薬会社は差別化要因として使いやすさと患者満足度に重点を置くようになっています。結局のところ、こうした技術の進歩は治療成果を高めると同時に、ユーザーエクスペリエンスを変革し、幅広い患者層に市場の魅力を広げているのです。

非従来型およびウェルネス・アプリケーションへの拡大

ヒト成長ホルモンの市場予測によると、市場は従来の医療用途にとどまらず、より幅広いウェルネス、スポーツ、美容用途へと拡大しています。HGHは現在でも成長ホルモン欠乏症やターナー症候群の治療薬として重要な役割を担っているが、アンチエイジング、筋肉増強、メタボリック・ウェルビーイングといった面でその良さが認識され、ライフスタイル市場や選択的ヘルスケア市場に波紋を広げています。ホルモン補充療法を提供するクリニックは、若々しく肉体的に健康であることを目指す高齢者層の間でますます人気が高まっています。このような適用には通常、規制当局の監視が必要であり、論争が絶えないが、長寿と生活の質に対する意識と関心の高まりに後押しされ、需要は依然として旺盛です。このため、従来の製薬会社が民間のウェルネス・クリニックや統合医療診療所と競合することになり、新たな市場力学が生まれつつあります。医療上の必要性とライフスタイルの向上との融合は、それゆえにいくつかの機会を生み出しています。その結果、HGH産業は、臨床上の必要性と消費者の要望の両方に支配される、高度に洗練されたエコシステムへと変貌しつつあります。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ

第10章 SWOT分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Eli Lilly and Company
- EMD Serono Inc.
- F. Hoffmann-La Roche AG
- Ferring B.V.
- Genentech Inc.
- Ipsen
- Merck KGaA
- Novartis AG
- Novo Nordisk
- Pfizer Inc.
- Sandoz

図表

List of Figures

Figure 1: Global: Human Growth Hormone Market: Major Drivers and Challenges
Figure 2: Global: Human Growth Hormone Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Human Growth Hormone Market: Breakup by Application (in %), 2024
Figure 4: Global: Human Growth Hormone Market: Breakup by Distribution Channel (in %), 2024
Figure 5: Global: Human Growth Hormone Market: Breakup by Route of Administration (in %), 2024
Figure 6: Global: Human Growth Hormone Market: Breakup by Region (in %), 2024
Figure 7: Global: Human Growth Hormone Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 8: Global: Human Growth Hormone (Growth Hormone Deficiency) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Human Growth Hormone (Growth Hormone Deficiency) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Human Growth Hormone (Turner Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Human Growth Hormone (Turner Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Human Growth Hormone (Idiopathic Short Stature- ISS) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Human Growth Hormone (Idiopathic Short Stature- ISS) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Human Growth Hormone (Prader-Willi Syndrome- PWS) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Human Growth Hormone (Prader-Willi Syndrome- PWS) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Human Growth Hormone (Small for Gestational Age) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Human Growth Hormone (Small for Gestational Age) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Human Growth Hormone (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Human Growth Hormone (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Human Growth Hormone (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Human Growth Hormone (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Human Growth Hormone (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Human Growth Hormone (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Human Growth Hormone (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Human Growth Hormone (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Human Growth Hormone (Others) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Human Growth Hormone (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Human Growth Hormone (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Human Growth Hormone (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: Global: Human Growth Hormone (Intramuscular) Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: Global: Human Growth Hormone (Intramuscular) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: Global: Human Growth Hormone (Subcutaneous) Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: Global: Human Growth Hormone (Subcutaneous) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Global: Human Growth Hormone (Oral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Global: Human Growth Hormone (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: North America: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: North America: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: United States: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: United States: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Canada: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Canada: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: Asia Pacific: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: Asia Pacific: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: China: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: China: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: Japan: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: Japan: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: India: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: India: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: South Korea: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: South Korea: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Australia: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Australia: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Indonesia: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Indonesia: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: Others: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: Others: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: Europe: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: Europe: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Germany: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Germany: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: France: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: France: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: United Kingdom: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: United Kingdom: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Italy: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Italy: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Spain: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Spain: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Russia: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Russia: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Others: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Others: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Latin America: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Latin America: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Brazil: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Brazil: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 78: Mexico: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 79: Mexico: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 80: Others: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 81: Others: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 82: Middle East and Africa: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
Figure 83: Middle East and Africa: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 84: Global: Human Growth Hormone Industry: SWOT Analysis
Figure 85: Global: Human Growth Hormone Industry: Value Chain Analysis
Figure 86: Global: Human Growth Hormone Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Human Growth Hormone Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Human Growth Hormone Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 3: Global: Human Growth Hormone Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 4: Global: Human Growth Hormone Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
Table 5: Global: Human Growth Hormone Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Human Growth Hormone Market: Competitive Structure
Table 7: Global: Human Growth Hormone Market: Key Players

Product Code: SR112025A2052

The global human growth hormone market size was valued at USD 6.11 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 11.47 Billion by 2033, exhibiting a CAGR of 6.88% during 2025-2033. North America currently dominates the market, holding a significant market share of 42.8% in 2024. The market is growing robustly due to the developed healthcare infrastructure and high incidence of HGH-related disorders like growth hormone deficiencies, Turner syndrome, and Prader-Willi syndrome. Government support in the form of favorable reimbursement policies, availability of leading pharmaceutical firms, including Pfizer and Eli Lilly, and advancements in recombinant DNA methods have also fueled the human growth hormone market share.

The market for human growth hormone (HGH) is witnessing rapid growth due to rising incidences of deficiencies of the growth hormone, including hyposomatotropism. Improvements in biotechnology and recombinant DNA technology have made it possible to produce synthetic HGH, and hence there is improvement in accessibility and affordability. The aging population and the resultant hormone deficiencies due to old age also create a strong demand for HGH therapies. Technological advancements in drug delivery systems, such as long-acting products and easy-to-use devices, improve patient compliance and ease of use. Moreover, increasing awareness among patients and medical practitioners regarding the advantages of HGH therapy helps support market growth. Growing healthcare infrastructure in developing economies provides untapped potential for market penetration. In addition, the growing trend of personalized medication and precision therapeutics enables specialized HGH therapies, maximizing yields and reducing adverse effects.

The United States stands out as a key market disruptor, driven by its advanced health system, robust regulatory system, and cutting-edge pharma landscape. American companies are at the forefront in creating new HGH products, such as long-acting and patient-friendly formulations, that are revolutionizing treatment patterns throughout the world. The proactive regulatory system of the country supports quick approval and commercialization of innovative therapies, leading the way for other global markets. Moreover, high awareness among patients and healthcare professionals also fuels early adoption of new treatments. Heavy investment in research and biotechnology further accelerates product innovation and competition, forcing global players to catch up with US standards. The incorporation of personalized medicine and digital health solutions also improves treatment accuracy and patient compliance. Consequently, the US shapes product development while also altering market expectations, positioning it as a trendsetter and a disruptor in the global HGH market space.

Human Growth Hormone Market Trends:

Growing Emphasis on Personalized and Preventive Therapies and Other Disorders

One of the most prominent trends transforming the human growth hormone (HGH) industry is growing emphasis on personalized and preventive healthcare methods. As medical science continues to evolve, treatments are departing from generic protocols to customized regimens specific to a patient's genetics, habits, and individual hormonal deficiencies. This trend is especially significant in the HGH market, where treatment duration and dosages can dramatically differ based on the patient's age, condition, and metabolic response. Doctors are increasingly using diagnostic tools and digital monitoring technologies to refine hormone therapies, producing improved results with fewer side effects. Preventive measures are also making inroads, with HGH being investigated for deficiency disorders, and also for age-related degeneration, trauma recovery, and chronic fatigue. Moreover, the increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes, occurring in approximately one in 2,500 female babies. Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. These expanded uses are broadening the market scope while responding to increasing consumer interest in wellness and longevity solutions, further fueling the human growth hormone market growth.

Technological Advances in Drug Delivery Systems

Several advancements in drug delivery systems are another principal trend propelling growth and innovation in the market for human growth hormone. Conventional HGH therapy was historically in the form of frequent, even daily injections, which imposed compliance challenges among pediatric and aged patients. The solution to this is the ongoing investment by the pharmaceutical industry to develop long-duration formulations, pen devices, and even transdermal patches and auto-injectors. These technologies are considerably improving patient convenience and treatment burden reduction, making HGH therapy more available and less daunting. Better drug delivery technology also improves stability in terms of hormone levels in the blood, reducing side effects and improving therapeutic efficacy. The trend is therefore an extension of a general shift toward patient-centered product design in the biopharmaceutical market. Moreover, with the rise in competition, pharmaceutical companies are focusing on ease of use and patient satisfaction as differentiators. Ultimately, these advances in technology are enhancing treatment outcomes, while also transforming user experience and broadening the market's appeal across a wide range of patient segments.

Expansion into Non-Traditional and Wellness Applications

The market is expanding beyond conventional medical applications into wider wellness, sports, and aesthetic uses, as per the human growth hormone market forecast. Although HGH is still an important therapy for growth hormone deficiency and Turner syndrome, its perceived virtues in anti-aging, muscle building, and metabolic well-being are creating waves in lifestyle and elective healthcare markets. Clinics that provide hormone replacement therapy are becoming increasingly popular among older age groups that aim to stay youthful and physically fit. While such applications are usually contentious and subject to regulatory oversight, demand remains strong, driven by increasing awareness and interest in longevity and quality of life. This is creating new market dynamics, as conventional pharmaceutical companies find themselves competing with private wellness clinics and integrative medicine practices. The convergence of medical necessity and lifestyle enhancement is hence giving rise to several opportunities. Consequently, the HGH industry is transforming itself into a highly sophisticated ecosystem as it is governed by both clinical necessities and consumer desires.

Human Growth Hormone Industry Segmentation:

Analysis by Application:

Growth Hormone (GH) Deficiency
- Adult GH Deficiency
- Pediatric GH Deficiency
Turner Syndrome
Idiopathic Short Stature (ISS)
Prader-Willi Syndrome (PWS)
Small for Gestational Age
Others

Growth hormone (GH) deficiency stands as the largest component in 2024. Growth hormone deficiency continues to dominate the human growth hormone (HGH) industry's leading applications segment, spearheaded by the proven clinical application and steady demand for both pediatrics and adult patient populations. GH deficiency among children can cause dwarfism, delayed puberty, and other aspects of developmental shortcomings, thus prompt diagnosis and management are imperative. Among adults, GH deficiency primarily manifests as lost muscle mass, lethargy, and declining metabolic function. The obvious therapeutic advantage of HGH in treating these symptoms guarantees long-term market demand. Physicians prescribe HGH therapy as routine treatment, underpinned by robust clinical guidelines and long-term outcome evidence. This segment also enjoys the advantage of ongoing research, which continues to optimize treatment protocols and enhance patient monitoring. The diagnosability of GH deficiency, along with improvements in diagnostic equipment and greater recognition by healthcare practitioners, reinforces its position as the cornerstone application supporting steady growth as observed throughout the human growth hormone market report.

Analysis by Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Hospital pharmacy leads the market with around 47.9% of market share in 2024. Hospital pharmacies are the primary channel of distribution in the human growth hormone (HGH) market because they can provide safe, regulated, and consistent access to hormone therapy. These pharmacies are usually the first point of dispensing for patients with complicated or chronic endocrine disorders, such as growth hormone deficiency. Hospitals provide an ordered setting for prescribing, administration, and patient supervision, a situation necessary for drugs requiring stringent dosing and monitoring. They are also generally centers for consolidated master plans involving treatment under specialists that endocrinologists and pediatricians coordinate, another guaranteeing element for them as a supplier of HGH. Moreover, hospitals are patient education centers and programs assuring maximization in therapeutic intervention. With stricter regulation and the necessity for high-standard storage and handling of biologics such as HGH, hospital pharmacies are adequately positioned to achieve compliance levels. Their place within larger healthcare delivery systems ensures that they are a reliable and trusted channel, playing an important role in ensuring the stability and growth of the HGH market.

Analysis by Route of Administration:

Intravenous
Intramuscular
Subcutaneous
Oral

Subcutaneous leads the market with around 33.7% of market share in 2024. Subcutaneous administration is the most predominant mode of administration in the human growth hormone (HGH) industry because it is effective, convenient, and patient-compliant. Subcutaneous injections are unlike intravenous (IV) injections, which must be administered under clinical observation, as they can be self-administered by patients in their own homes, thus the best for maintenance hormone therapy. This technique consists of injecting HGH into the fat tissue directly under the skin, so it can be slowly and steadily absorbed into the body. It is also less intrusive than other techniques, with lower risks of complications like infection or damage to the blood vessels. With time, improvements in the injection equipment, including pre-filled syringes, auto-injectors, and pen devices, have further simplified subcutaneous administration. These innovations increase patient comfort, simplify the treatment process, and enhance compliance. Considering these factors, subcutaneous injections are the favored and most adopted mode of administration for HGH treatments, fueling growth within the HGH market.

Regional Analysis:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

In 2024, North America accounted for the largest market share of over 42.8%. North America is the leading regional segment in the worldwide human growth hormone (HGH) market, fueled by a mix of sophisticated healthcare infrastructure, strong research and development activities, and a high incidence of growth hormone deficiencies. The United States, especially, is instrumental, with a major market share due to its well-established healthcare systems and pervasive availability of HGH therapies. This dominance is complemented by supportive reimbursement policies and government actions that enable patient access to treatments that are essential. Major pharmaceutical corporations headquartered in North America, including Pfizer and Eli Lilly, drives the market growth by ensuring ongoing innovation and the establishment of new HGH products. While, these innovations enhance the effectiveness of treatments, they also optimize patient compliance and quality of life. The region's dedication to healthcare excellence guarantees a consistent demand for HGH treatments, cementing its status as the top market segment. In the future, North America's market share is likely to continue its upward growth, driven by continued investment in healthcare infrastructure and growing public awareness about growth hormone deficiency. With the region continuing to dominate both in terms of market size and innovation, it also sets the standard for HGH therapy practice globally.

Key Regional Takeaways:

United States Human Growth Hormone Market Analysis

In 2024, the United States accounted for over 91.80% of the human growth hormone market in North America. The United States human growth hormone (HGH) market is witnessing sustained growth, driven by increasing awareness about hormone-related disorders and a growing emphasis on physical health and wellness. An increase in the elderly population, with the count of Americans aged 65 and above expected to reach 82 million by 2050, is fueling the rising demand for hormone replacement therapies (PRB). Additionally, the expanding use of HGH in managing conditions associated with growth hormone deficiency and improved diagnostic capabilities is fueling market demand. Supportive healthcare infrastructure, along with a rise in specialized treatment centers, further boosts market growth. Technological advancements in drug delivery methods and increasing healthcare expenditure are enhancing accessibility and treatment adherence. The expanding scope of therapeutic applications beyond traditional uses is also stimulating market interest. Investment in medical research, regulatory support, personalized medicine, preventive healthcare, fitness consciousness, hormone therapy uses, digital health integration, and early diagnosis awareness are driving market growth.

Europe Human Growth Hormone Market Analysis

The human growth hormone market in Europe is expanding steadily due to increased recognition of endocrine disorders and broader acceptance of hormonal therapies. An aging demographic and the growing focus on improving quality of life are fueling the demand for growth hormone treatment options. The European Pharmaceutical Review states that biosimilar competition in Europe has significantly increased patient access to key biological medicines, with healthcare budget reductions amounting to €56 billion across Europe and approx. €6 billion in 2024 alone. This trend supports the wider adoption of growth hormone therapies by making them more affordable and accessible. The market for hormone therapies is thriving due to advancements in healthcare systems, advanced diagnostic tools, research and development efforts, public health initiatives, digital technology integration, continuous medical education programs, and the growing perception of hormone therapies as part of overall wellness strategies. With rising healthcare investments and a focus on preventive care, the market is poised for continued expansion.

Asia Pacific Human Growth Hormone Market Analysis

The Asia Pacific human growth hormone market outlook is experiencing robust growth, fueled by increasing healthcare awareness and rising demand for hormone-based therapies. Improved healthcare access and infrastructure across developing regions are enhancing diagnosis and treatment rates. A growing population and a heightened focus on child development are also contributing to market expansion. According to the India Brand Equity Foundation, the Indian healthcare market, valued at USD 110 Billion in FY16, is now projected to reach USD 638 Billion by FY25, further indicating the growing healthcare needs in the region. The adoption of advanced medical technologies and an escalating interest in personalized treatment are strengthening therapeutic approaches. Enhanced government health initiatives and greater public awareness about hormone-related disorders are accelerating market activity. Furthermore, the demand for better quality of life and rising investment in medical innovation are supporting long-term growth. The market outlook remains positive, driven by changing lifestyle patterns and increased health consciousness across urban populations.

Latin America Human Growth Hormone Market Analysis

The Latin American human growth hormone market is expanding due to increased public awareness, healthcare coverage, and improved medical infrastructure. The market is driven by a rising focus on growth and developmental health, hormone therapy adoption, and general wellness promotion. Additionally, the region is benefitting from continuous initiatives aimed at improving healthcare service delivery, as Brazil's local manufacturing of medical supplies satisfies 42% of the population's requirements. With the New Industry Brazil (NIB) initiative, the government seeks to elevate this percentage to 50% by 2026 and to 70% by 2033, which will enhance market potential by facilitating access to therapeutic solutions. These combined initiatives are setting the area up for ongoing expansion in the HGH market.

Middle East and Africa Human Growth Hormone Market Analysis

The Middle East and Africa human growth hormone market is expanding due to increased awareness about endocrine health, improved healthcare access, investments in medical facilities, health education, demand for advanced therapies, and long-term wellness focus. This growth is fueled by increased support for health infrastructure. Additionally, the growing medical tourism sector in the region plays a significant role in market expansion. With ongoing developments in healthcare provision and a shift toward preventive care practices, the market is poised for further advancement. These factors collectively contribute to the promising outlook of the region's HGH market.

Competitive Landscape:

Major companies in the human growth hormone market are developing growth through different strategic initiatives, such as product development innovation, strategic alliances, and increased patient accessibility programs. Major pharmaceuticals like Novo Nordisk, Pfizer, Eli Lilly, and Merck are investing in developing future-generation HGH products, including long-acting or sustained-release products, that decrease the number of injections and increase patient compliance. These innovations are intended to make treatment more convenient for pediatric as well as adult patients, resulting in better therapeutic results. These firms also invest heavily on research and development to identify new uses for HGH, such as in anti-aging and metabolic health, broadening the scope of the market beyond conventional deficiency treatments. Additionally, key players are establishing strategic alliances and partnerships with healthcare professionals, academic centers, and research centers to increase market presence and widen clinical evidence backing HGH treatments. These partnerships facilitate quicker product development and lead to bringing new solutions to the market more efficiently. In order to enhance patient accessibility, firms are collaborating with payers and regulatory agencies to rationalize approval processes and make HGH therapies widely available and affordable. Consequently, these initiatives are driving market growth, improving the overall efficacy of HGH treatment, and responding to the heterogeneous needs of the patient base.

The report provides a comprehensive analysis of the competitive landscape in the human growth hormone market with detailed profiles of all major companies, including:

Eli Lilly and Company
EMD Serono Inc.
F. Hoffmann-La Roche AG
Ferring B.V.
Genentech Inc.
Ipsen
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Sandoz

Key Questions Answered in This Report

1.How big is the human growth hormone market?
2.What is the future outlook of human growth hormone market?
3.What are the key factors driving the human growth hormone market?
4.Which region accounts for the largest human growth hormone market share?
5.Which are the leading companies in the global human growth hormone market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Human Growth Hormone Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Application

6.1 Growth Hormone (GH) Deficiency
- 6.1.1 Market Trends
- 6.1.2 Major Types
  - 6.1.2.1 Adult GH Deficiency
  - 6.1.2.2 Pediatric GH Deficiency
- 6.1.3 Market Forecast
6.2 Turner Syndrome
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Idiopathic Short Stature (ISS)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Prader-Willi Syndrome (PWS)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Small for Gestational Age
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast

7 Market Breakup by Distribution Channel

7.1 Hospital Pharmacy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Retail Pharmacy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Online Pharmacy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Intravenous
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Intramuscular
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Subcutaneous
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Oral
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Eli Lilly and Company
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 EMD Serono Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
- 13.3.3 F. Hoffmann-La Roche AG
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 SWOT Analysis
- 13.3.4 Ferring B.V.
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
- 13.3.5 Genentech Inc.
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 SWOT Analysis
- 13.3.6 Ipsen
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
- 13.3.7 Merck KGaA
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
- 13.3.8 Novartis AG
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
- 13.3.9 Novo Nordisk
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
- 13.3.10 Pfizer Inc.
  - 13.3.10.1 Company Overview
  - 13.3.10.2 Product Portfolio
  - 13.3.10.3 Financials
  - 13.3.10.4 SWOT Analysis
- 13.3.11 Sandoz
  - 13.3.11.1 Company Overview
  - 13.3.11.2 Product Portfolio

ヒト成長ホルモンの市場規模、シェア、動向、予測：用途、流通チャネル、投与経路、地域別、2025年～2033年

Human Growth Hormone Market Size, Share, Trends and Forecast by Application, Distribution Channel, Route of Administration, and Region, 2025-2033

ヒト成長ホルモン市場動向：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のヒト成長ホルモン市場

第6章 市場内訳：用途別

第7章 市場内訳：流通チャネル別

第8章 市場内訳：投与経路別

第9章 市場内訳：地域別

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 競合情勢